Business Description
Oryzon Genomics SA
ISIN : ES0167733015
Compare
Compare
Traded in other countries / regions
ORY.SpainORN.Germany0RDB.UKORY.MexicoORYZF.USA IPO Date
2015-12-17Description
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -6.1 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 3.7 | |||||
3-Year FCF Growth Rate | 2.3 | |||||
3-Year Book Growth Rate | -2.2 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.31 | |||||
9-Day RSI | 54.72 | |||||
14-Day RSI | 51.22 | |||||
6-1 Month Momentum % | -0.62 | |||||
12-1 Month Momentum % | -8.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.9 | |||||
Shareholder Yield % | -2.37 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -3.71 | |||||
ROA % | -2.78 | |||||
ROIC % | -1.33 | |||||
ROC (Joel Greenblatt) % | -427.69 | |||||
ROCE % | -2.53 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.39 | |||||
Price-to-Tangible-Book | 1.44 | |||||
EV-to-EBIT | -52.15 | |||||
EV-to-Forward-EBIT | -38.54 | |||||
EV-to-EBITDA | -53.98 | |||||
EV-to-Forward-EBITDA | -40.18 | |||||
EV-to-Forward-Revenue | 18.98 | |||||
EV-to-FCF | -8.31 | |||||
Earnings Yield (Greenblatt) % | -1.91 | |||||
FCF Yield % | -12.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oryzon Genomics SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.048 | ||
Beta | -0.08 | ||
Volatility % | 19.18 | ||
14-Day RSI | 51.22 | ||
14-Day ATR (€) | 0.033657 | ||
20-Day SMA (€) | 1.8481 | ||
12-1 Month Momentum % | -8.08 | ||
52-Week Range (€) | 1.602 - 2.36 | ||
Shares Outstanding (Mil) | 63.77 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oryzon Genomics SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oryzon Genomics SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Oryzon Genomics SA Frequently Asked Questions
What is Oryzon Genomics SA(LTS:0RDB)'s stock price today?
The current price of LTS:0RDB is €1.88. The 52 week high of LTS:0RDB is €2.36 and 52 week low is €1.60.
When is next earnings date of Oryzon Genomics SA(LTS:0RDB)?
The next earnings date of Oryzon Genomics SA(LTS:0RDB) is 2024-08-30 Est..
Does Oryzon Genomics SA(LTS:0RDB) pay dividends? If so, how much?
Oryzon Genomics SA(LTS:0RDB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |